This practice parameter is for both FDG and amyloid brain PET or PET/computed tomography (CT) for patients with cognitive decline, and has been developed collaboratively by the American College of Radiology (ACR) and the American Society for Neuroradiology (ASNR). It is estimated that the number of people with dementia, 36.5 million worldwide in 2010, will increase to 65.7 million in 2030 and to 115 million in 2050. Four primary neurodegenerative etiologies of dementia have been defined: Alzheimer disease (AD), vascular dementia, frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB). Alzheimer disease is the most common form of dementia, accounting for approximately 60%-80% of all cases. Indications for FDG and amyloid brain PET and qualifications for personnel are discussed in this practice parameter.
Practice parameters and technical standards are published annually with an effective date of October 1 in the year in which amended, revised, or approved by the ACR Council. For practice parameters and technical standards published before 1999, the effective date was January 1 following the year in which the practice parameter or technical standard was amended, revised, or approved by the ACR Council. Development chronology for this practice parameter: 2015 (Resolution 21 care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set forth in this document when, in the reasonable judgment of the practitioner, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology subsequent to publication of this document. However, a practitioner who employs an approach substantially different from the guidance in this document is advised to document in the patient record information sufficient to explain the approach taken.
The practice of medicine involves not only the science, but also the art of dealing with the prevention, diagnosis, alleviation, and treatment of disease. The variety and complexity of human conditions make it impossible to always reach the most appropriate diagnosis or to predict with certainty a particular response to treatment. Therefore, it should be recognized that adherence to the guidance in this document will not assure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources, and the needs of the patient to deliver effective and safe medical care. The sole purpose of this document is to assist practitioners in achieving this objective.
I. INTRODUCTION
This practice parameter has been developed collaboratively by the American College of Radiology (ACR) and the American Society for Neuroradiology (ASNR).
It is estimated that the number of people with dementia, 36.5 million worldwide in 2010, will increase to 65.7 million in 2030 and to 115 million in 2050, a result of changed demographics and increased longevity. 1 This poses great challenges for both society and health care systems. 2 Four primary neurodegenerative etiologies of dementia have been defined: Alzheimer disease (AD), vascular dementia, frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB). 3 Alzheimer disease is the most common form of dementia, accounting for approximately 60%-80% of all cases. 4 The most prominent clinical feature of AD is an early impairment of episodic memory, 5 which manifests as memory impairment for recent events, unusual repeated omissions, and difficulty learning new information. As the disease progresses, the symptoms often manifest in more persistent language disturbance and difficulties completing more complex tasks of daily living. The early stage of cognitive decline, namely mild cognitive impairment (MCI), is the intermediate phase between normality and dementia during which patients show cognitive decline confirmed on objective cognitive testing but do not meet criteria for dementia since independent function is generally preserved. 6 Those with MCI convert to AD at a rate of about 10% to 25% annually compared to healthy elders who convert at a rate of about 1% to 2% annually. 3 About 20% of MCI patients progress to other dementia types, and 30% to 40% of cases do not progress to dementia. 7 The original diagnostic criteria for AD rested on the notion that AD is a clinical-pathological entity. The diagnosis is classified as definite (clinical diagnosis with histologic confirmation), probable (typical clinical syndrome without histologic confirmation), or possible AD (atypical clinical features but no alternative diagnosis apparent; no histologic confirmation). Note that possible AD may be identified by unusual or atypical features but also by the presence of an alternative or contributory pathology, such as prior significant head trauma, alcohol-substance abuse, cerebrovascular disease, etc. A diagnosis of definite AD is only made according to criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria when there is histopathologic confirmation of the clinical diagnosis. 8 With research progress, distinctive biomarkers of the disease are now recognized, including structural brain changes visible on magnetic resonance imaging (MRI), molecular neuroimaging changes seen with positron emission tomography (PET), and changes in cerebrospinal fluid (CSF) biomarkers. These biomarkers can be divided into 2 major categories: 1) the biomarkers of A-beta (Aß) amyloid accumulation: abnormal radiopharmaceutical retention on amyloid PET imaging and low CSF Aß-42 peptide and 2) the biomarkers of neuronal degeneration or injury: elevated CSF tau protein (both total and phosphorylated tau); decreased F-18 fluorodeoxyglucose (FDG) uptake on PET in a specific topographic pattern involving posterior cingulate/precuneus and temporoparietal cortex; and atrophy on structural magnetic resonance, again in a specific topographic pattern involving medial, basal, and lateral temporal lobes and medial and lateral parietal cortices. 9 Biomarkers of Aß amyloid are indicative of initiating upstream events that may deviate from normal before clinical symptoms manifest. Biomarkers of neuronal injury and neuronal dysfunction are indicative of downstream pathophysiological processes that temporally follow. 9 Current evidence suggests that amyloid biomarkers may become abnormal approximately 10 to 20 years before noticeable clinical symptoms. Progression of clinical symptoms closely parallels progressive worsening of neurodegenerative biomarkers. 6, 10, 11 Biomarkers of neurodegeneration are now being incorporated into clinical diagnostic criteria for specific disorders. [12] [13] [14] In 2004, the Center for Medicare and Medicaid Services (CMS) issued a positive coverage decision (NCD 220.6.13) for the use of FDG-PET to distinguish AD versus FTD. 15 It was determined that FDG-PETwas reasonable and necessary only in patients with recent development of dementia who met diagnostic criteria for AD and FTD. The National Coverage Determination also contained a second and broader element for FDG-PET in the diagnosis of dementia under coverage with evidence development. In 2012, the FDA approved the first amyloid PET radiopharmaceutical (florbetapir) for imaging of the brain for Aß-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive decline.
A negative scan indicates sparse to no amyloid neuritic plaques and thus is not consistent with a neuropathological diagnosis of AD at the time of the scan. A negative scan reduces the likelihood that a patient's cognitive impairment is due to AD. A positive amyloid scan indicates moderate to severe amyloid neuritic plaques and can be seen in AD and dementia with Lewy bodies (DLB. Positive scans may be obtained in patients with mild cognitive impairment and in older people with normal cognition who are at increased risk for progressing to MCI and AD. 16 This ACR practice parameter is for both FDG and amyloid brain PET or PET/computed tomography (CT) for patients with cognitive decline.
II. DEFINITIONS
For the purposes of this practice parameter, the following definitions apply: PET/CT scanner: A device that includes a single patient table for obtaining a PET scan, a CT scan, or both. If the patient stays reasonably immobile between the scans, the PET and CT data are aligned and can be accurately fused. PET/CT acquisition: The process of collecting PET/CT data. In the context of brain imaging, data will be acquired from the vertex to the base of the skull. Typically this range will be encompassed by the axial field-of-view of the PET system, ie, no bed translation during PET data acquisition. PET/CT registration: The process of taking PET and CT image sets that represent the same brain volume and aligning them such that there is a voxel-by-voxel match for the purpose of combined image display (fusion) or image analysis. PET/CT fusion: The simultaneous display (superimposed or not) of registered PET and CT image sets. When superimposed, the image sets are typically displayed with the PET data colorcoded onto the grayscale CT data.
III. INDICATIONS
A. FDG-PET Imaging of regional glucose metabolism with the radiopharmaceutical F-18 FDG can provide unique neuronal metabolism information in patients with cognitive decline and dementia. Symptoms and signs of cognitive disorders are manifestations of synaptic and neuronal dysfunction and losses in neurodegenerative diseases. Regional patterns of altered glucose metabolism, as imaged with FDG-PET, can indicate the presence of a neurodegenerative process and can characterize involvement of individual cerebral structures and pathways. FDG-PET studies should be performed at the request of physicians knowledgeable in clinical diagnosis and management of dementia and under circumstances where the results of the examination are likely to have an impact on patient care. Examples of indications for FDG-PET imaging in cognitive decline and dementia include, but are not limited to, the following:
1. Assessment of progressive dementia: Although AD is the most common cause of dementia in the elderly, several other neurodegenerative conditions exist that may be responsible for progressive dementia in the individual patient. FDG-PET can identify the underlying characteristic brain regional patterns of cerebral hypometabolism and can thereby distinguish AD from other degenerative processes such as FTD. 17 
Assessment of neurodegeneration in subjects with MCI: Several
studies support the utility of FDG-PET to identify patients with a course of progressive cognitive decline attributable to a neurodegenerative condition before the onset of clinically diagnosed dementia. Although the use of FDG-PET has not been determined to be useful for screening of asymptomatic patients who may ultimately be at risk of developing dementia, the modality can be useful in patients who meet the criteria for MCI. [18] [19] [20] 
B. Amyloid-PET
Clinical molecular imaging of cerebral fibrillar Aß-amyloid deposition is based in large part on results obtained with the use of the research radiopharmaceutical 11C-Pittsburgh Compound-B (PiB; [11C] 6-HO-BTA-1). The FDA has recently approved radiofluorinated radiopharmaceuticals (florbetapir, flutemetemol, and florbetaben) for clinical use. The FDA approvals were based on the demonstration that in vivo tracer imaging correlated with the extent or severity of postmortem neuritic plaques in end-oflife patients. 21, 22 The biodistribution and imaging characteristics of these newer radiopharmaceuticals, and the indications below, are predicated in part on the basis of findings with PiB, with the expectation that the clinical radiopharmaceuticals have similar discriminatory properties. 7 Pathological depositions of fibrillar Aßamyloid are requisite for the pathological diagnosis of AD 23 and are found as well in many instances of related neurodegenerative disorders, most frequently in cases of DLB. Non-neurodegenerative disorders such as primary cerebral amyloid angiopathy may be amyloid PET-positive. 24 Evolving understanding of the relationships among amyloid deposition, synaptic dysfunction, and losses of neurons and synapses in AD suggest that the amyloid-driven aspects of the pathophysiology occur prior to losses of neurons and synapses, perhaps by many years. 25 Thus, it is anticipated that Aß-amyloid imaging may be more specific than FDG-PET in differentiating among degenerative dementias, but it may not necessarily provide evidence of a specific neurodegenerative cause of early cognitive complaints in nondemented patients.
The use of amyloid imaging is recommended to determine presence (or absence) of pathological fibrillar Aß-amyloid deposition in patients with progressive cognitive decline or dementia of uncertain etiology in whom AD is a possibility. Amyloid-PET studies should be performed at the request of physicians knowledgeable in clinical diagnosis and management of dementia and under circumstances where the results of the examination are likely to impact patient care. Indications for amyloid-PET imaging in cognitive decline and dementia include, but are not limited to, the following:
Detection of Alzheimer pathology in cognitively impaired adults: Subjects with progressive cognitive decline who demonstrate features atypical of AD and suggestive of another neurodegenerative process such as FTD (eg, early age of onset, prominent behavioral dysregulation, or primary progressive aphasia) may have atypical AD presentations or may have FTD. Patients with FTD do not demonstrate abnormal levels of amyloid deposition at pathology evaluation and do not have increased binding of amyloid radiopharmaceuticals in PET imaging. A negative amyloid PET scan is inconsistent with Alzheimer pathology and suggests that AD does not account for symptoms and signs of progressive cognitive decline.
At the present time, clinical amyloid-PET imaging has not been validated for screening asymptomatic subjects with genetic or other risk factors for developing AD or in subjects without a clinical diagnosis of a progressive cognitive decline or dementia as established by a clinician expert in the assessment and management of dementing disorders. In addition, amyloid PET cannot be used to establish the diagnosis of AD or monitor the response to therapy for AD in terms of disease progression or improvement. A negative amyloid-PET study indicates absence of significant ß-amyloid plaques at the time of the study and does not exclude the future development of these plaques.
IV. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL
A. Physician PET/CT examinations of the brain should be performed under the supervision of and interpreted by a physician who meets qualifications outlined in the ACR-SNM Technical Standard for Diagnostic Procedures Using Radiopharmaceuticals 26 : and Initial Education and Experience For brain FDG PET/CT: 1. Six hours of CME in brain FDG PET/CT interpretation for dementia. 2. Thirty proctored or over-read brain FDG PET/CT scans performed for investigation of dementia prior to beginning unsupervised interpretation. 3. Live or online education programs may be used to fulfill these requirements.
For brain amyloid PET/CT: 1. Three hours of CME in brain amyloid PET/CT interpretation. Live or online educational programs may be used to fulfill this requirement. 2. Interpretation of brain PET images to estimate β-amyloid neuritic plaque density should be performed only by readers who successfully complete a special training program such as one sponsored by the manufacturer of one of the FDAapproved radiopharmaceuticals. Live or online educational programs may be used to fulfill this requirement.
Continuing Education and Experience
For continuing education and experience, please see the ACR-SNM Technical Standard for Diagnostic Procedures Using Radiopharmaceuticals 26 and ACR Practice Parameter for Continuing Medical Education. 27 
B. Qualified Medical Physicist
For qualified medical physicist qualifications, see the ACR-AAPM Technical Standard for Medical Physics Performance Monitoring of PET/CT Imaging Equipment. 28 
C. Radiologic and Nuclear Medicine Technologist
See the ACR Practice Parameter for Performing and Interpreting Diagnostic Computed Tomography (CT) 29 and the ACR-SNM Technical Standard for Diagnostic Procedures Using Radiopharmaceuticals. 26 Representatives of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Radiologic Technologists (ASRT) met in 2002 to discuss training technologists for PET/CT. The recommendations from that consensus conference for training technologists for PET/CT are outlined in the subsequent article published. 30 As a consequence of this conference and ensuing educational recommendations, cross-training and continuing educational programs have been developed to educate radiologic, radiation therapy, and nuclear medicine technologists in PET/CT fusion imaging.
The Nuclear Medicine Technology Certification Board (NMTCB) has developed a PET specialty examination that is open to appropriately educated and trained, certified, or registered nuclear medicine technologists, registered radiologic technologists, CT technologists, and registered radiation therapists, as defined on the NMTCB website (www.nmtcb.org). The American Registry of Radiologic Technologists (ARRT) offers a CT certification examination for qualified radiologic technologists and allows certified or registered nuclear medicine technologists who meet the educational and training requirements to take this examination. Eligibility criteria are located on the ARRT website (www.arrt.org).
D. Radiation Safety Officer
The radiation safety officer must meet applicable requirements of the Nuclear Regulatory Commission (NRC) for training as specified in 10 CFR 35.50 or equivalent state regulations.
V. BRAIN PET/CT EXAMINATION SPECIFICATIONS
A. The written or electronic request for a PET/CT examination of the brain should provide sufficient information to demonstrate the medical necessity of the examination and allow for its proper performance and interpretation. Documentation that satisfies medical necessity includes 1) signs and symptoms and/or 2) relevant history (including known diagnoses). Additional information regarding the specific reason for the examination or a provisional diagnosis would be helpful and may at times be needed to allow for the proper performance and interpretation of the examination.
The request for the examination must be originated by a physician or other appropriately licensed health care provider. The accompanying clinical information should be provided by a physician or other appropriately licensed health care provider familiar with the patient's clinical problem or question and consistent with the state scope of practice requirements. ( Note: With PET/CT, the radiation dose to the patient is the combination of the administered activity from the PET radiopharmaceutical and the dose from the CT portion of the examination. Lower administered activities may be appropriate with longer imaging times and advances in PET/CT technology.
D. Patient Positioning
1. Careful positioning of the patient's head in the center of the camera's field of view is critical. 2. The patient should be informed of the need to remain still throughout the scan, and a head holder may diminish movement artifacts. With dementia patients, a comfortable head position, rather than straight, may reduce motion artifacts. 3. Continuous supervision of the patient during the whole scanning procedure is necessary. This is especially important for patients with cognitive impairment. 4. Conscious sedation using a short-acting benzodiazepine for agitation may be needed in selected patients. Sedating medications should be given at least 20 minutes after radiopharmaceutical injection, preferably close to PET/CT acquisition.
E. Protocol for CT Imaging
The CT performed as part of a PET/CT examination provides diagnostic information that may be relevant to both PET interpretation and overall patient care. A variety of protocols exist for performing the CT scan in the context of PET/CT scanning. In most cases, low-dose CT scans are utilized to provide attenuation correction and anatomic localization, as the patient will often have an existing MR of the head. In patients where an MR is contraindicated, the CT portion of the examination can be performed as an optimized brain CT with standard brain CT imaging parameters if ordered by the referring physician. Regardless of the CT technique used, a careful review of CT images is necessary for comprehensive interpretation of the PET/CT examination. Patient positioning should be optimized to minimize radiation dose to the lens. F. Protocol for PET Imaging 1. A standardized acquisition protocol with a fixed acquisition start time is useful so comparable data are obtained each time, whether from different patients or repeat scans in the same patient. PET emission acquisition should commence 35 to 60 minutes after FDG administration and 30 to 60 minutes after administration of F-18 amyloid binding radiopharmaceutical. 2. The duration of emission acquisition will depend on the performance characteristics of the individual scanner system, but a minimum of 10 minutes in 3-D mode is recommended. 3. PET data should be normalized for detector/geometric effects and corrected for random coincidences, dead time, scatter, and attenuation. Non-attenuation-corrected (NAC) images should also be reconstructed to assess patient motion. 4. If patient movement is a particular concern, the PET/CT scan can be performed as a dynamic acquisition (eg, 5 2-minute frames). The dynamic images may be evaluated for motion and the intact data added together prior to final reconstruction. List-mode acquisitions can be used for the same purpose. 5. Images should be reconstructed so as to have a pixel size less than 2 mm in the transverse plane. 6. Iterative or analytic reconstruction methods are acceptable, although consistent technique is important. 7. Reconstruction parameters will depend on injected activity, scanner, acquisition parameters, available software, and the interpreting physician's preference.
G. Interpretation
1.
With an integrated PET/CT system, the software packages typically provide a comprehensive platform for image review. 2. A standard brain image review is recommended to ensure rapid, accurate, and reproducible interpretations. Internal landmark reorientation should be used to achieve standardized image display. 3. The images should be critically examined prior to interpretation for technical quality, especially evidence of movement. Non-attenuation-corrected PET images should be used to assess motion between CT and PET acquisitions. 4. Fused PET/CT images are helpful to identify motion and evaluate functional-structural findings simultaneously. Fusion of PET with MRI is desirable in select individuals. 5. Review of coronal and sagittal images is highly recommended. 6. Known morphological changes, such as atrophy, must be factored into interpretation of PET data. 7. Three-dimensional display of the dataset (eg, by volume rendering or surface projections such as 3-D stereotactic surface projection (SSP) can be helpful for detection of disease patterns. 8. Comparison to an appropriately normative database obtained under similar acquisition settings may improve diagnostic accuracy.
VI. EQUIPMENT SPECIFICATIONS
See the ACR-ASNR Practice Parameter for the Performance of Computed Tomography (CT) of the Brain 31 and the ACR-AAPM Technical Standard for Medical Physics Performance Monitoring of PET/CT Imaging Equipment. 28 
A. Performance Parameters
For patient imaging, the PET/CT scanner should meet or exceed the following specifications: 1. For the PET scanner a. In-plane spatial resolution: <6. 
VII. DOCUMENTATION
Reporting should be in accordance with the ACR Practice Parameter for Communication of Diagnostic Imaging Findings. 32 
VIII. EQUIPMENT QUALITY CONTROL
PET/CT performance monitoring should be in accordance with the ACR-AAPM Technical Standard for Medical Physics Performance Monitoring of PET/CT Imaging Equipment. 28 Administered activity calibrator performance monitoring should be in accordance with the ACR-SNM Technical Standards for Diagnostic Procedures Using Radiopharmaceuticals. 26 The accuracy of administered activity calibrators used for F-18 should ideally be measured using Germanium-68 standards, crosscalibrated for F-18 and traceable to a national metrology lab.
Specific requirements for PET/CT brain imaging include quarterly testing with an F-18 fillable phantom such as the ACRapproved PET phantom. Phantom images should be analyzed using the appropriate clinical workstations wherever possible. Qualitative assessment should include confirmation that PET and CT images are free from artifacts, particularly side-to-side gradients in intensity. The accuracy of the spatial registration of the PET and CT images should ideally be assessed quantitatively, although qualitative assessment is acceptable. The centers of the phantom inserts should be closely aligned on PET and CT with no systematic differences across the images. The uniform region of the PET images should have a standard uptake value in the range 0.9 to 1.1, with a target range of 0.95 to 1.05. Resolution recovery of the phantom inserts should be stable over time, and current measurements should be consistent with previous data, eg, mean ± 2 SD of prior measurements.
A check of the performance of both the PET and CT components is required every day that the scanner is to be used and should be performed prior to patient imaging. The nature of these procedures will vary between scanner systems, and manufacturer recommendations should be followed. For PET, such tests should include verification of PET detector integrity, which involves a quantitative comparison of various detector parameters to reference values. Daily CT quality control should include a scan of a standard CTwater phantom. The accuracy of the resulting CT numbers and image noise should be recorded.
When not indicated by the manufacturer's daily recommendations, a Ge-68 cylinder phantom is recommended for periodic assessment of PET/CT system stability. Additional use of this phantom is recommended after scanner maintenance or scheduled scanner recalibration and should be performed prior to patient imaging.
The dates and results of all quality control procedures should be recorded.
IX. RADIATION SAFETY IN IMAGING
Radiologists, medical physicists, registered radiologist assistants, radiologic technologists, and all supervising physicians have a responsibility for safety in the workplace by keeping radiation exposure to staff, and to society as a whole, "as low as reasonably achievable" (ALARA) and to assure that radiation doses to individual patients are appropriate, taking into account the possible risk from radiation exposure and the diagnostic image quality necessary to achieve the clinical objective. All personnel that work with ionizing radiation must understand the key principles of occupational and public radiation protection (justification, optimization of protection and application of dose limits) and the principles of proper management of radiation dose to patients (justification, optimization and the use of dose reference levels) http://www-pub.iaea.org/ MTCD/Publications/PDF/Pub1578_web-57265295.pdf.
Facilities and their responsible staff should consult with the radiation safety officer to ensure that there are policies and procedures for the safe handling and administration of radiopharmaceuticals and that they are adhered to in accordance with ALARA. These policies and procedures must comply with all applicable radiation safety regulations and conditions of licensure imposed by the Nuclear Regulatory Commission (NRC) and by state and/or other regulatory agencies. Quantities of radiopharmaceuticals should be tailored to the individual patient by prescription or protocol.
Nationally developed guidelines, such as the ACR's Appropriateness Criteria®, should be used to help choose the most appropriate imaging procedures to prevent unwarranted radiation exposure.
Additional information regarding patient radiation safety in imaging is available at the Image Gently® for children (www. imagegently.org) and Image Wisely® for adults (www.imagewisely. org) websites. These advocacy and awareness campaigns provide free educational materials for all stakeholders involved in imaging (patients, technologists, referring providers, medical physicists, and radiologists 
X. RADIOPHARMACEUTICALS QUALITY CONTROL
A. FDG F-18 FDG is taken up by cells and phosphorylated to 18 F-FDG-6-phosphate ( 18 F-FDG-6P) at a rate proportional to the rate of glucose utilization within a given tissue. 18 F-FDG-6phosphate (Fluorodeoxyglucose F18-FDG-6P) is not metabolized further in the glycolytic pathway (it is not a substrate for hexose phosphate isomerase) and is relatively trapped in the cell. In some cells, 18 F-FDG-6-phosphate may be dephosphorylated back to 18 F-fluorodeoxyglucose via glucose-6-phosphatase. This pathway is relatively minor in brain, skeletal muscle, and cardiac muscle, permitting PET imaging of the accumulated 18 F-FDG-6P in these target tissues. Many neoplasms have similar high phosphorylation to dephosphorylation rates, resulting in trapping of F-18 FDG and retention of 18 F-FDG-6P. F-18 FDG that is not involved in glucose metabolism is excreted unchanged in the urine.
B. Amyloid-avid Radiotracers
As of June 2014, the US FDA has approved the use of three amyloid-avid radiotracers for human imaging of fibrillar amyloid deposition in the brain. Each of the tracers has the fundamental property of binding to fibrillar Aβ-amyloid aggregates, and results in highly similar brain images in subjects with and without pathologic amyloid deposition. 7 Amyvid contains florbetapir F-18 and is described as (E)-4- The time-activity curves for the amyloid tracers in the brains of subjects with positive scans are similar across the individual agents, showing continual signal increases from time zero through 30 approximately minutes post-administration with stable values thereafter up to at least 90 minutes post-injection. Differences in the signal intensity between portions of the brain that specifically retain the amyloid tracer and the portions of the brain with nonspecific retention form the basis of image interpretation. The specific binding of the radiotracers to Aβ-amyloid aggregates was demonstrated in postmortem human brain sections using autoradiographic methods, thioflavin S, and traditional silver-staining correlation studies as well as monoclonal antibody Aβ-amyloid-specific correlation studies. Radiotracer binding to tau protein aggregates and alpha-synuclein aggregates and a battery of neuroreceptors was not detected in in vitro studies. Tracer specific binding to fibrillar Aβ-amyloid aggregates in vivo was confirmed for each of the tracers in comparison to autopsy measures of amyloid burden.
XI. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION
Policies and procedures related to quality, patient education, infection control, and safety should be developed and implemented in accordance with the ACR Policy on Quality Control and Improvement, Safety, Infection Control, and Patient Education appearing under the heading Position Statement on QC & Improvement, Safety, Infection Control, and Patient Education on the ACR website (http://www.acr.org/guidelines).
For specific issues regarding CT quality control, see the ACR Practice Parameter for Performing and Interpreting Diagnostic Computed Tomography (CT). 29 For specific issues regarding PET and PET/CT quality control, see section VIII on Equipment Quality Control.
Equipment performance monitoring should be in accordance with the ACR-AAPM Technical Standard for Diagnostic Medical Physics Performance Monitoring of Computed Tomography (CT) Equipment. 33 
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